Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis

NASDAQ:APLS - US03753U1060 - Common Stock

27.57 USD
-0.48 (-1.71%)
Last: 8/29/2025, 8:06:37 PM
27.57 USD
0 (0%)
After Hours: 8/29/2025, 8:06:37 PM
Fundamental Rating

3

Taking everything into account, APLS scores 3 out of 10 in our fundamental rating. APLS was compared to 542 industry peers in the Biotechnology industry. APLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. APLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

APLS had negative earnings in the past year.
APLS had a positive operating cash flow in the past year.
APLS had negative earnings in each of the past 5 years.
In the past 5 years APLS always reported negative operating cash flow.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

APLS's Return On Assets of -27.78% is fine compared to the rest of the industry. APLS outperforms 69.93% of its industry peers.
APLS's Return On Equity of -145.98% is on the low side compared to the rest of the industry. APLS is outperformed by 62.18% of its industry peers.
Industry RankSector Rank
ROA -27.78%
ROE -145.98%
ROIC N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Gross Margin of APLS (83.78%) is better than 86.90% of its industry peers.
In the last couple of years the Gross Margin of APLS has declined.
The Profit Margin and Operating Margin are not available for APLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

APLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APLS has more shares outstanding
APLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for APLS has been reduced compared to a year ago.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

APLS has an Altman-Z score of -1.30. This is a bad value and indicates that APLS is not financially healthy and even has some risk of bankruptcy.
APLS has a Altman-Z score (-1.30) which is in line with its industry peers.
APLS has a debt to FCF ratio of 102.86. This is a negative value and a sign of low solvency as APLS would need 102.86 years to pay back of all of its debts.
APLS has a Debt to FCF ratio of 102.86. This is amongst the best in the industry. APLS outperforms 91.14% of its industry peers.
A Debt/Equity ratio of 2.90 is on the high side and indicates that APLS has dependencies on debt financing.
APLS's Debt to Equity ratio of 2.90 is on the low side compared to the rest of the industry. APLS is outperformed by 81.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.9
Debt/FCF 102.86
Altman-Z -1.3
ROIC/WACCN/A
WACC9.86%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

APLS has a Current Ratio of 3.77. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.77, APLS perfoms like the industry average, outperforming 43.73% of the companies in the same industry.
A Quick Ratio of 3.16 indicates that APLS has no problem at all paying its short term obligations.
APLS has a Quick ratio (3.16) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.77
Quick Ratio 3.16
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.00% over the past year.
The Revenue has grown by 20.02% in the past year. This is a very strong growth!
Measured over the past years, APLS shows a very strong growth in Revenue. The Revenue has been growing by 127.23% on average per year.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
Revenue 1Y (TTM)20.02%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-10.61%

3.2 Future

The Earnings Per Share is expected to grow by 29.06% on average over the next years. This is a very strong growth
APLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.92% yearly.
EPS Next Y45.53%
EPS Next 2Y16.42%
EPS Next 3Y31.08%
EPS Next 5Y29.06%
Revenue Next Year20.45%
Revenue Next 2Y8.62%
Revenue Next 3Y12.87%
Revenue Next 5Y14.92%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6 -8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 91.14% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 788.81
EV/EBITDA N/A
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

APLS's earnings are expected to grow with 31.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.42%
EPS Next 3Y31.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (8/29/2025, 8:06:37 PM)

After market: 27.57 0 (0%)

27.57

-0.48 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners102.53%
Inst Owner Change2.26%
Ins Owners3.74%
Ins Owner Change0.01%
Market Cap3.48B
Analysts77.86
Price Target38.53 (39.75%)
Short Float %20.72%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.16%
Min EPS beat(2)-101.36%
Max EPS beat(2)31.03%
EPS beat(4)2
Avg EPS beat(4)-23.58%
Min EPS beat(4)-101.36%
Max EPS beat(4)31.03%
EPS beat(8)4
Avg EPS beat(8)-13.22%
EPS beat(12)6
Avg EPS beat(12)-8.14%
EPS beat(16)6
Avg EPS beat(16)-8.9%
Revenue beat(2)0
Avg Revenue beat(2)-11.79%
Min Revenue beat(2)-16.4%
Max Revenue beat(2)-7.17%
Revenue beat(4)1
Avg Revenue beat(4)-5.55%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)5.05%
Revenue beat(8)4
Avg Revenue beat(8)-0.89%
Revenue beat(12)7
Avg Revenue beat(12)7.11%
Revenue beat(16)9
Avg Revenue beat(16)40.14%
PT rev (1m)6.34%
PT rev (3m)-10.05%
EPS NQ rev (1m)10575.1%
EPS NQ rev (3m)312.23%
EPS NY rev (1m)55.14%
EPS NY rev (3m)59.34%
Revenue NQ rev (1m)37.28%
Revenue NQ rev (3m)64.05%
Revenue NY rev (1m)8.79%
Revenue NY rev (3m)18.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.61
P/FCF 788.81
P/OCF 775.29
P/B 22.28
P/tB 22.28
EV/EBITDA N/A
EPS(TTM)-1.82
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)0.03
FCFY0.13%
OCF(TTM)0.04
OCFY0.13%
SpS5.98
BVpS1.24
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.78%
ROE -145.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.78%
FCFM 0.58%
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 2.9
Debt/FCF 102.86
Debt/EBITDA N/A
Cap/Depr 4.29%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.77
Quick Ratio 3.16
Altman-Z -1.3
F-Score4
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
EPS Next Y45.53%
EPS Next 2Y16.42%
EPS Next 3Y31.08%
EPS Next 5Y29.06%
Revenue 1Y (TTM)20.02%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-10.61%
Revenue Next Year20.45%
Revenue Next 2Y8.62%
Revenue Next 3Y12.87%
Revenue Next 5Y14.92%
EBIT growth 1Y39.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.7%
EBIT Next 3Y50.05%
EBIT Next 5Y35.88%
FCF growth 1Y100.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.72%
OCF growth 3YN/A
OCF growth 5YN/A